Inloggen
E-mail
Wachtwoord
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON
  1. Homepagina
  2. Aandelen
  3. Denemarken
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. Onderneming
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
Real-time geschatte koers. Geschatte realtime Cboe Europe - 14/06 09:55:12
514.6 DKK   -0.43%
10/06NOVO NORDISK† : Goldman Sachs geeft koopadvies
MD
10/06NOVO NORDISK† : Een koopadvies van Bernstein
MD
10/06NOVO NORDISK† : JP Morgan herhaalt koopadvies
MD
OverzichtKoersenGrafiekenNieuwsRatingenAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
Beroep
Logo Novo Nordisk A/S
Novo Nordisk AS specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:

- products for treating diabetes and obesity (84.3%);

- hemophilia treatment products (8.4%): mainly injections of protein;

- growth hormones (6%): used for treatment of growth deficiencies in children;

- hormone replacement products (1.3%): used for treatment of the menopause and prevention of osteoporosis.

Net sales are distributed geographically as follows: Europe (19.1%), the United States (47.1%), North America (2.5%), Africa/Asia/Middle East/Oceania (11.5%), China (10.5%), Japan and Korea (5.3%) and Latin America (4%).

Aantal werknemers : 45 323 mensen.
Verkoop per activiteit
20192020Delta
DKK (in miljoenen)%DKK (in miljoenen)%
Diabetes and Obesity Care102 84084.3%108 02085.1% +5.04%
Biopharm19 18115.7%18 92614.9% -1.33%
Verkoop per regio
2020
DKK (in miljoenen)%
United States57 82445.6%
EMEA34 29727%
Rest of the World17 44813.7%
China14 08411.1%
Canada3 2932.6%
Managers
NaamLeeftijdVanTitel
Lars Fruergaard Jorgensen542017President & Chief Executive Officer
Karsten Munk Knudsen492018Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen60-Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff502019Executive VP & Head-Information Technology
Stephen Gough-2015Global Chief Medical Officer
Maziar Mike Doustdar502016Executive Vice President-International Operations
Elizabeth Anne Hewitt642012Independent Director
Sylvie Louise Grťgoire, Dr.592015Independent Director
Brian F. Daniels, Dr.612016Independent Director
Helge Lund582018Chairman
Bestuurders
NaamLeeftijdVanTitel
Helge Lund582018Chairman
Anne Marie Handrup Kverneland642000Director
Stig StrÝbśk571998Director
Elizabeth Anne Hewitt642012Independent Director
Jeppe Fonager Christiansen612013Vice Chairman
Sylvie Louise Grťgoire, Dr.592015Independent Director
Brian F. Daniels, Dr.612016Independent Director
Kasim Kutay552017Member-Supervisory Board
Mette BÝjer Jensen452018Director
Thomas Rantzau482018Director
Aandelen
Stemming AantalPercentage vrij verhandelbaarZelf controlerenDrijvend Totaal
Aandeel A 10 537 000 000 0 0.0% 0 0.0% 69.8%
Aandeel B 1 1 772 564 000 1 612 733 341 91.0% 37 500 000 2.1%
Aandeelhouders
NaamAandelen%
Novo Holdings A/S (Investment Company) 116 129 000 6,55%
Norges Bank Investment Management 43 498 435 2,45%
The Vanguard Group, Inc. 40 178 414 2,27%
Alecta Pension Insurance Mutual 27 085 444 1,53%
BlackRock Fund Advisors 26 690 203 1,51%
Fundsmith LLP 20 525 100 1,16%
BlackRock Investment Management (UK) Ltd. 18 376 161 1,04%
Capital Research & Management Co. (World Investors) 16 895 809 0,95%
Handelsbanken Fonder AB 15 721 299 0,89%
Flossbach von Storch AG 13 895 000 0,78%
Belangnemingen
NaamAandelen%Totale waarde
Novo Nordisk A/S (NOVO B) 12 620 1920,71%998 544 801 USD
NNIT A/S (NNIT) 4 375 00017,5%91 053 681 USD
Innate Pharma (IPH) 9 817 54612,4%36 586 460 USD
Markten en indices
-
- Main Market Large
- OMXC 20 / Low Carbon 100 Europe, NASDAQ OMX Nordic 120, OMX Nordic 40, PEA, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200
Beurscodes
- Bloomberg Code :  NOVOB:DC
- Reuters Code :  NOVOb.CO
- Datastream code :  DK:NON
Bedrijfsgegevens
Novo Nordisk A/S
Novo Allť
DK-2880 Bagsvaerd


Telefoon : +45 44 44 88 88
Fax : +45 44 49 05 55
Internet : http://www.novonordisk.com
Merk portefeuille
In samenwerking metMijn merken op de beurs
Meer merken vanNovo Nordisk A/S
Sector Farmaceutische producten - Andere
Verschil t.o.v. 1 jan (%)Marktkapitalisatie (M$)
NOVO NORDISK A/S21.13%193 164
JOHNSON & JOHNSON4.82%434 405
ROCHE HOLDING AG10.68%328 612
PFIZER, INC.9.07%224 747
NOVARTIS AG-0.39%208 035
ABBVIE INC.7.72%203 857
ELI LILLY AND COMPANY32.72%203 704
MERCK & CO., INC.-6.76%193 120
ASTRAZENECA PLC13.87%154 435
BRISTOL-MYERS SQUIBB COMPANY8.56%150 360
AMGEN INC.5.59%139 484
SANOFI12.96%134 500
GLAXOSMITHKLINE PLC4.58%99 056
JIANGSU HENGRUI MEDICINE CO., LTD.-21.45%72 637
CHUGAI PHARMACEUTICAL CO., LTD.-20.44%65 563
ALLERGAN PLC0.97%63 659
BAYER AG11.04%63 542
TAKEDA PHARMACEUTICAL COMPANY LIMITED0.64%53 877
DAIICHI SANKYO COMPANY, LIMITED-27.20%44 921
ASTELLAS PHARMA INC.20.98%32 631
EISAI CO., LTD.45.14%27 948